Cable Hill Partners’s United Therapeutics UTHR Stock Holding History

Cable Hill Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-223	Closed	-$28K	–	842
2018 Q3	$28K	Hold	223	–	–	0.01%	265
2018 Q2	$25K	Hold	223	–	–	0.01%	294
2018 Q1	$25K	Hold	223	–	–	0.01%	304
2017 Q4	$33K	Buy	223 +123	+123%	+$15.6K	0.01%	297
2017 Q3	$12K	Hold	100	–	–	0.01%	531
2017 Q2	$13K	Hold	100	–	–	0.01%	352
2017 Q1	$14K	Hold	100	–	–	0.01%	335
2016 Q4	$14K	Hold	100	–	–	0.01%	337
2016 Q3	$12K	Hold	100	–	–	0.01%	391
2016 Q2	$11K	Buy	+100	New	+$11.2K	0.01%	364

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cable Hill Partners's UTHR Position: Q4 2018 in Review

Cable Hill Partners sold out of United Therapeutics (UTHR) in Q4 2018, closing a stake of 223 shares — an estimated $28K sold.

Cable Hill Partners first reported a position in UTHR in Q2 2016 and held it in 10 quarters. The position peaked at $33K in Q4 2017. 360 funds tracked by Wall St. Rank hold UTHR as of Q4 2018.

Cable Hill Partners reported no remaining United Therapeutics position as of Q4 2018 after selling out during the quarter.
Cable Hill Partners sold 223 United Therapeutics shares in Q4 2018, an estimated $28K.
Cable Hill Partners first reported a position in United Therapeutics in Q2 2016 and held it in 10 quarters.
Cable Hill Partners's United Therapeutics position peaked at $33K in Q4 2017.
360 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2018.

Based on Cable Hill Partners's 13F filing for Q4 2018, filed 12 Feb 2019.